Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
Cardiol Therapeutics expanded its U.S. Phase III MAVERIC trial network to up to 25 sites, adding premier institutions like the Cleveland Clinic and Mayo Clinic to accommodate growing investigator interest. Patient enrollment in the pivotal study has reached 75%, accelerating from the 50% milestone achieved in early January, with full recruitment targeted by the end of Q2 2026.
Key figures
- Target patients
- 110
- Enrollment percentage
- 75%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.